ALK and non-small cell lung carcinoma: By using NSCLC cell lines harbouring ALK, ROS1, RET and NTRK1 fusions, Vaishnavi et al. also confirmed that EGFR signalling was involved at different levels in determining the resistance to multi-kinase inhibitors so that treatment with gefitinib was able to abrogate EGFR contributions [25].